Developer docs
API playgroundTry for free, no card

Search company profiles

EnteroMedics

Full company profile

uuid00062e7

Namestring
EnteroMedics
Websiteurl
enteromedics.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

EnteroMedics Inc. (formerly NASDAQ: ETRM) was a Saint Paul, Minnesota-based medical device company founded in 2002, operating with 11-50 employees and focused on developing neuromodulation therapies for obesity and obesity-related metabolic conditions. The company's core technology centered on vagus nerve stimulation (commonly branded as vBloc), an implantable neuromodulation platform positioned within the broader internal neuromodulation devices market, where it competed against materially larger incumbents including Medtronic, Boston Scientific, and Nevro Corp. The addressable market was sizable: the internal neuromodulation devices segment was projected to reach $4.24B by 2030 at a 9.2% CAGR, and the vagus nerve stimulation market was projected to grow from $10.67B in 2024 to $23.73B by 2031 at a 10.50% CAGR.

The company's product and revenue model is not fully detailed in the source material. No pricing, reimbursement, sales channel, or unit-shipment data is disclosed, and no revenue figure is available. The customer base is described as spanning obesity-treatment patients, patients with neurological disorders treatable by vagus nerve stimulation (epilepsy, depression, migraine, chronic pain), and the healthcare providers who implant the device, implying a B2B2C commercial model in which physician adoption drives patient throughput. The company funded its operations through at least ten disclosed funding rounds totaling roughly $160M+ between 2004 and 2017, with the 2017 cohort (~$100.1M across four rounds) coinciding with two acquisitions: BarioSurg (May 2017, undisclosed) and ReShape Lifesciences (October 2017, $61M), the latter signaling a pivot toward a broader bariatric device portfolio. Investors included Aberdare Ventures, Bay City Capital, and MPM Capital (2010 round). The company is now delisted from NASDAQ and its corporate domain has been redirected to unrelated content, indicating that the original operating entity is no longer active in its prior form; the analysis here describes the company as it existed through 2017.

Short descriptiontext

EnteroMedics was a Saint Paul-based medical device company (founded 2002) that developed implantable vagus nerve stimulation therapies targeting obesity and related metabolic conditions, serving patients and healthcare providers in the broader internal neuromodulation market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Paul, United States
HQ citystring
Saint Paul
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
bariatric weight loss, vagus nerve stimulation, neuromodulation devices, obesity treatment, metabolic therapy
Industry1 code
1Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
CodeHLAHAEAKPrimaryYes
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Bariatric / Neuromodulation Medical Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EnteroMedics develops and commercializes implantable vagus nerve stimulation (vBloc) medical devices for the treatment of obesity and obesity-related risk factors. The company's neuromodulation systems are deployed internally in patients and used by healthcare providers as a non-pharmaceutical alternative for weight management and metabolic control.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • The internal neuromodulation devices market is projected to reach $4.24 billion by 2030 with a CAGR of 9.2%
+1 more record
Product and service2 records
1vBloc / Vagus Nerve Stimulation (VNS) Neuromodulation System
CategoryBariatric / Neuromodulation Medical Devices
2Vagus Nerve Stimulation Therapy (Neurological Indications)
CategoryNeurological Neuromodulation Therapy
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Medtronic
TypeBroad incumbent
Description

Global medical device leader with a broad neuromodulation portfolio including VNS (for epilepsy and depression), DBS, SCS, and PNS. Direct competitor to EnteroMedics across the implantable neurostimulation category with far greater scale and commercial reach.

2Boston Scientific
TypeBroad incumbent
Description

Large diversified medtech with significant neuromodulation and spinal cord stimulation franchises. Competes in the same implantable neurostimulation market as EnteroMedics with extensive hospital sales coverage.

3Nevro Corp
TypeDirect peer
Description

Pure-play implantable neuromodulation company (10 kHz HF10 therapy for chronic pain). Directly comparable to EnteroMedics as a focused neurostim device company competing against large incumbents.

4LivaNova
TypeDirect peer
Description

Owns the legacy Cyberonics VNS franchise (VNS Therapy) for epilepsy and depression, the closest direct competitor to EnteroMedics' vagus nerve stimulation platform.

5Inspire Medical Systems
TypeDirect peer
Description

Developer of an implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a small-cap, focused implantable neurostim company that scaled into a commercial leader.

6NeuroPace
TypeEmerging player
Description

Developer of the RNS System, a closed-loop implantable neurostim for epilepsy. Comparable in scale, technology category (implantable neurostim), and indication overlap to EnteroMedics.

7ReShape Lifesciences
TypeDirect peer
Description

Bariatric and obesity device company (Lap-Band, ReShape Balloon, vBloc) that was acquired by EnteroMedics in 2017. Direct overlap in the obesity device category and historical peer.

8Apollo Endosurgery
TypeDirect peer
Description

Developer of endoscopic weight loss solutions (Orbera intragastric balloon, OverStitch suturing system). Direct peer in the non-surgical bariatric and obesity device market.

9electroCore
TypeEmerging player
Description

Developer of non-invasive vagus nerve stimulation (gammaCore) for migraine and cluster headache. Adjacent VNS-focused peer sharing target indications with EnteroMedics.

10Stryker
TypeBroad incumbent
Description

Large diversified medtech with surgical, orthopedic, and neuromodulation-adjacent businesses. Relevant as a potential strategic acquirer of obesity/neurostim assets and as an incumbent in adjacent device categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EnteroMedics

Bariatric / Neuromodulation Medical Devicesenteromedics.com

EnteroMedics was a Saint Paul-based medical device company (founded 2002) that developed implantable vagus nerve stimulation therapies targeting obesity and related metabolic conditions, serving patients and healthcare providers in the broader internal neuromodulation market.

What EnteroMedics does

EnteroMedics Inc. (formerly NASDAQ: ETRM) was a Saint Paul, Minnesota-based medical device company founded in 2002, operating with 11-50 employees and focused on developing neuromodulation therapies for obesity and obesity-related metabolic conditions. The company's core technology centered on vagus nerve stimulation (commonly branded as vBloc), an implantable neuromodulation platform positioned within the broader internal neuromodulation devices market, where it competed against materially larger incumbents including Medtronic, Boston Scientific, and Nevro Corp. The addressable market was sizable: the internal neuromodulation devices segment was projected to reach $4.24B by 2030 at a 9.2% CAGR, and the vagus nerve stimulation market was projected to grow from $10.67B in 2024 to $23.73B by 2031 at a 10.50% CAGR.

The company's product and revenue model is not fully detailed in the source material. No pricing, reimbursement, sales channel, or unit-shipment data is disclosed, and no revenue figure is available. The customer base is described as spanning obesity-treatment patients, patients with neurological disorders treatable by vagus nerve stimulation (epilepsy, depression, migraine, chronic pain), and the healthcare providers who implant the device, implying a B2B2C commercial model in which physician adoption drives patient throughput. The company funded its operations through at least ten disclosed funding rounds totaling roughly $160M+ between 2004 and 2017, with the 2017 cohort (~$100.1M across four rounds) coinciding with two acquisitions: BarioSurg (May 2017, undisclosed) and ReShape Lifesciences (October 2017, $61M), the latter signaling a pivot toward a broader bariatric device portfolio. Investors included Aberdare Ventures, Bay City Capital, and MPM Capital (2010 round). The company is now delisted from NASDAQ and its corporate domain has been redirected to unrelated content, indicating that the original operating entity is no longer active in its prior form; the analysis here describes the company as it existed through 2017.

EnteroMedics firmographics

Firmographics
Name
EnteroMedics
Website
https://enteromedics.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
EnteroMedics was a Saint Paul-based medical device company (founded 2002) that developed implantable vagus nerve stimulation therapies targeting obesity and related metabolic conditions, serving patients and healthcare providers in the broader internal neuromodulation market.
Ownership category
akta.pro rank

EnteroMedics industry classification

Industry
Product category
Bariatric / Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

  • Bariatric weight loss
  • Vagus nerve stimulation
  • Neuromodulation devices
  • Obesity treatment
  • Metabolic therapy

Where EnteroMedics is headquartered

Location

Headquarters

HQ city
Saint Paul
HQ country
United States
HQ region
North America

Markets served

EnteroMedics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

EnteroMedics product offering

Product offering

Core offering

EnteroMedics develops and commercializes implantable vagus nerve stimulation (vBloc) medical devices for the treatment of obesity and obesity-related risk factors. The company's neuromodulation systems are deployed internally in patients and used by healthcare providers as a non-pharmaceutical alternative for weight management and metabolic control.

Differentiator

Problem solved

Functional benefit

Products and services

  • vBloc / Vagus Nerve Stimulation (VNS) Neuromodulation System
  • Vagus Nerve Stimulation Therapy (Neurological Indications)

Quantifiable outcome

  • The internal neuromodulation devices market is projected to reach $4.24 billion by 2030 with a CAGR of 9.2%
  • +1 more outcomes

Companies that use EnteroMedics

Customer profile

Segments3 records

Ideal customer profiles2 records

EnteroMedics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EnteroMedics partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

EnteroMedics competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Global medical device leader with a broad neuromodulation portfolio including VNS (for epilepsy and depression), DBS, SCS, and PNS. Direct competitor to EnteroMedics across the implantable neurostimulation category with far greater scale and commercial reach.
  • Boston Scientific: Large diversified medtech with significant neuromodulation and spinal cord stimulation franchises. Competes in the same implantable neurostimulation market as EnteroMedics with extensive hospital sales coverage.
  • Stryker: Large diversified medtech with surgical, orthopedic, and neuromodulation-adjacent businesses. Relevant as a potential strategic acquirer of obesity/neurostim assets and as an incumbent in adjacent device categories.

Direct peers

  • Nevro Corp: Pure-play implantable neuromodulation company (10 kHz HF10 therapy for chronic pain). Directly comparable to EnteroMedics as a focused neurostim device company competing against large incumbents.
  • LivaNova: Owns the legacy Cyberonics VNS franchise (VNS Therapy) for epilepsy and depression, the closest direct competitor to EnteroMedics' vagus nerve stimulation platform.
  • Inspire Medical Systems: Developer of an implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a small-cap, focused implantable neurostim company that scaled into a commercial leader.
  • ReShape Lifesciences: Bariatric and obesity device company (Lap-Band, ReShape Balloon, vBloc) that was acquired by EnteroMedics in 2017. Direct overlap in the obesity device category and historical peer.
  • Apollo Endosurgery: Developer of endoscopic weight loss solutions (Orbera intragastric balloon, OverStitch suturing system). Direct peer in the non-surgical bariatric and obesity device market.

Emerging players

  • NeuroPace: Developer of the RNS System, a closed-loop implantable neurostim for epilepsy. Comparable in scale, technology category (implantable neurostim), and indication overlap to EnteroMedics.
  • electroCore: Developer of non-invasive vagus nerve stimulation (gammaCore) for migraine and cluster headache. Adjacent VNS-focused peer sharing target indications with EnteroMedics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

EnteroMedics social profiles

Digital presence

EnteroMedics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EnteroMedics leadership team

Management profile

Number of profiles

Profiles4 records

EnteroMedics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EnteroMedics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnteroMedics

What does EnteroMedics do?

EnteroMedics develops and commercializes implantable vagus nerve stimulation (vBloc) medical devices for the treatment of obesity and obesity-related risk factors. The company's neuromodulation systems are deployed internally in patients and used by healthcare providers as a non-pharmaceutical alternative for weight management and metabolic control.

Is EnteroMedics a public or private company?

EnteroMedics is a private company. It is classified as unknown and is currently operating.

When was EnteroMedics founded?

EnteroMedics was founded in 2002. It employs 11 to 50 people.

Where is EnteroMedics based?

EnteroMedics is headquartered in Saint Paul, United States, in the North America region.

Who are EnteroMedics's main competitors?

Broad incumbents on record are Medtronic, Boston Scientific and Stryker. Direct peers are Nevro Corp, LivaNova, Inspire Medical Systems, ReShape Lifesciences and Apollo Endosurgery. Emerging players are NeuroPace and electroCore.

Does EnteroMedics have an API?

No public API is recorded for EnteroMedics.

What industry is EnteroMedics in?

EnteroMedics's product category is Bariatric / Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Bariatric (Obesity) Surgical Devices Market Analysis & Forecasts (2016-2024) - 2018 Strategic Business ReportResearchAndMarkets published a strategic business report providing comprehensive analysis of the global bariatric surgical devices market for the period 2016–2024, covering segments such as gastric bypass, gastric banding, and sleeve gastrectomy across major regions including the US, Europe, Asia-Pacific, and Latin America. The report profiles 26 companies including key players such as Medtronic, Apollo Endosurgery, and Ethicon, identifying rising global obesity prevalence as the primary growth driver and examining competitive dynamics, FDA approvals, and technological innovations. Notable industry developments cited include ValenTx's $10.3 million fundraising, EnteroMedics' acquisition of ReShape Medical, and multiple regulatory clearances for intragastric balloon systems in various markets.PR NewswireEnteroMedics Announces Name Change to ReShape Lifesciences Inc. (NASDAQ: RSLS)EnteroMedics Inc. officially changed its name to ReShape Lifesciences Inc. on October 23, 2017, with the new ticker symbol RSLS, reflecting the company's transformation from a single-product obesity treatment provider to a comprehensive medical device company. The name change was driven by recent acquisitions of ReShape Medical, Inc. and BarioSurg, Inc., which expanded the company's portfolio to include multiple FDA-approved weight loss devices and an investigational Gastric Vest System. The corporate structure, stockholder rights, and outstanding stock certificates remain unchanged following the name transition.PR NewswireEnteroMedics Announces New Employee Inducement Option GrantsEnteroMedics Inc. announced that its Compensation Committee granted stock options covering 1,255,000 shares to 51 newly hired employees resulting from the company's acquisition of ReShape Medical, Inc., along with a separate 240,000-share option to newly hired VP Deborah Schmalz. The options have a 10-year term, vest over four years, and were granted under NASDAQ Listing Rule 5635(c)(4) as employment inducement awards. The grants were effective October 6, 2017, with exercise prices set at the closing price on that date.PR NewswireEnteroMedics Announces Acquisition Of ReShape MedicalEnteroMedics Inc. announced on October 3, 2017 the acquisition of ReShape Medical, Inc., a privately-held medical technology company that developed the FDA-approved ReShape Dual Weight Loss Balloon for treating obesity patients with a BMI between 30 and 40. The transaction consideration consisted of 2,356,729 shares of common stock, 187,772 shares of series C convertible preferred stock convertible into 18,777,200 shares of common stock, and approximately $5.0 million in cash used to pay ReShape Medical's outstanding senior secured indebtedness and transaction expenses. The acquisition adds a non-surgical weight loss solution to EnteroMedics' portfolio and expands the company's addressable market along the continuum of care in obesity treatment.PR NewswireEnteroMedics to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceEnteroMedics Inc., a medical device company focused on treating obesity and metabolic diseases, announced it will present at the Ladenburg Thalmann 2017 Healthcare Conference in New York on September 26, 2017. The company's management will deliver the presentation at 11:00AM ET, with a webcast available through the investors section of EnteroMedics' website. The company also noted its recent acquisition of the Gastric Vest System through BarioSurg, Inc., expanding its portfolio of obesity treatment technologies.PR NewswireEnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc TherapyEnteroMedics Inc. has initiated the ReNEW Study, a five-year post-approval clinical trial to evaluate the long-term safety and effectiveness of its vBloc System for treating obesity in real-world settings. The multi-center trial involves enrolling 200 patients across approximately 10-15 U.S. centers to assess excess weight loss and serious adverse events.PR NewswireStudy Concludes Vagal Nerve Blocking with EnteroMedics' vBloc Therapy is Cost-EffectiveA study published in the American Journal of Managed Care on August 25, 2017 concluded that EnteroMedics' vBloc Therapy for vagal nerve blocking is likely cost-effective for Class II and III obese patients with diabetes and Class III obese patients without diabetes, compared to conventional weight loss therapy. The study, led by Boston Health Economics, found that incremental cost effectiveness ratios demonstrated the therapy to be cost-effective from a U.S. payer perspective. EnteroMedics stated this publication brings them closer to increasing accessibility to vBloc for individuals for whom the cost of the technology is currently prohibitive.PR NewswireEnteroMedics Announces Pricing of $20 Million Underwritten Public OfferingEnteroMedics Inc., a medical device company focused on obesity and metabolic disease treatments, has priced an underwritten public offering of units for gross proceeds of $20 million, with closing expected on or about August 16, 2017. The offering comprises 20,000 units at $1,000 per unit, each consisting of series B convertible preferred stock convertible into 435 shares of common stock and a seven-year warrant, both at a conversion and exercise price of $2.30 per share. The company intends to use the net proceeds for continued commercialization of its vBloc System, clinical and product development activities, and other working capital and general corporate purposes.PR NewswireEnteroMedics Announces Proposed Underwritten Public OfferingEnteroMedics Inc., a St. Paul-based medical device company focused on obesity and metabolic disease treatments, announced on August 10, 2017 the commencement of an underwritten public offering consisting of units with one share of series B convertible preferred stock and one warrant per unit. Ladenburg Thalmann & Co. Inc. is serving as sole book-running manager, and the company plans to use net proceeds for commercialization of its vBloc System, clinical and product development activities, and general corporate purposes.PR NewswireEnteroMedics Announces Second Quarter 2017 Financial ResultsEnteroMedics Inc. reported second quarter 2017 financial results, placing a record 42 vBloc commercial units, representing an 83% increase year-over-year, though quarterly sales declined to $93,000 compared to $276,000 in Q2 2016, with the company posting a net loss of $6.84 million. The company announced the acquisition of BarioSurg, Inc. and its Gastric Vest System, and received Spanish regulatory approval to begin CE Mark study proceedings. As of June 30, 2017, EnteroMedics held $11.2 million in cash with no debt.